Last reviewed · How we verify
EU Remicade
At a glance
| Generic name | EU Remicade |
|---|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Infusion related reaction
- Alanine aminotransferase increased
Key clinical trials
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects (PHASE1)
- A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02). (PHASE3)
- A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01) (PHASE1)
- Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EU Remicade CI brief — competitive landscape report
- EU Remicade updates RSS · CI watch RSS
- Samsung Bioepis Co., Ltd. portfolio CI